Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22013972 | 0.91 | — | — | |
| SCHEMBL19543355 | 0.91 | — | — | |
| SCHEMBL2478796 | 0.85 | CA12 (0.35) | PIK3CD | |
| SCHEMBL20438325 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL21026948 | 0.78 | — | — | |
| SCHEMBL20445489 | 0.77 | — | — | |
| SCHEMBL17914516 | 0.74 | — | — | |
| SCHEMBL21142720 | 0.72 | — | — | |
| SCHEMBL105108 | 0.71 | CYP1A2 (0.31) | — | |
| SCHEMBL19772670 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152086-A1 | METHODS FOR TREATING MUSCULAR DYSTROPHY WITH CASIMERSEN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-05-19 | — | — | US | disclosed |
| WO-2021152149-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-08-05 | — | — | WO | disclosed |
| US-20210102205-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | US | disclosed |
| EP-3315531-A1 | 8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2018-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152086-A1 | METHODS FOR TREATING MUSCULAR DYSTROPHY WITH CASIMERSEN | UTRN, SMN1; SMN2, MTPN | PIK3CD 678/4885 |
| US-20210102205-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, RBM17, UPF1 | PIK3CD 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.